HOMEWORK ASSIGNMENT - Please Read.
Some of us want to disseminate relevant information on LL. I copied CTMedic's summary and edited it. Can some of you look it over and make sure it reads correctly?
I want to send it to persons who may have influence (whatever that means)
The web links do not work but will by the time I start sending it.
There is one kicker. I have no science background. Just editing. I have to sign it and put down CTMedic from this board. Should I just sign my name and this board? Unsure. It has to be legit.
To Whom it May Concern
CytoDyn, a small biotech company in Vancouver, WA has developed Leronlimab, a potent therapeutic for COVID-19 among other diseases. I own stock in CytoDyn and I am one of many shareholders who has volunteered to disseminate information of Leronlimab’s success when treating patients suffering from COVID-19.
There are hundreds of vaccines and therapeutics in development for COVID-19 and to date none with significant clinical effect. However, Leronlimab is a monoclonal antibody (mAb) with demonstrated efficacy in treating COVID-19 and the associated cytokine storm of immune dysregulation. A clinical trial of Leronlimab has been completed for the (M/M) mild/moderate patient population. This (M/M) trial demonstrated clinical and statistical significance and a request has been submitted to the FDA for (EUA) Emergency Use Authorization.
Leronlimab blocks the binding site of the CCR5 receptor on macrophages, T lymphocytes, and eosinophils. This stops chemotaxic trafficking of immune cells to areas of inflammation, halting the inflammatory cascade and the cytokine storm. Furthermore, blocking of CCR5 repolarizes macrophages and reverses exhaustion of CD8 lymphocytes, permitting normal immune function and resumption of antiviral activity through natural killer T-cells and granzyme-A antiviral production. In other words, by day 3, the COVID sufferer is already on the mend and within seven days is usually released from the hospital.
Former Stanford University Virologist, Dr. Bruce Patterson, described this mechanism of Leronlimab in a preprint on May 5: “Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277012/
CytoDyn has submitted top line data from a double blinded, placebo-controlled study to the FDA. Leronlimab demonstrates statistically significant improvement in NEWS2 (National Early Warning Score), a widely accepted UK clinical metric for measuring the progression of COVID-19 into the severe/critical phase. (P=0.02). Leronlimab showed clinical improvement in the NEWS2 score by 150%.
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19: https://clinicaltrials.gov/ct2/show/NCT043436...amp;rank=3
In addition, Leronlimab has demonstrated reduced mortality in the severe/critical population in over 70 EIND (Emergency Investigational New Drug) patients. A phase 3 trial is ongoing for this population, with an interim analysis of the data due in the coming weeks.
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19):
https://clinicaltrials.gov/ct2/show/NCT043472...amp;rank=4
CytoDyn does not yet have an FDA approval in any indication, so with cessation of EIND (Emergency Investigational New Drug) Leronlimab is unavailable to patients outside of clinical trial sites.
Please research CytoDyn, and reach out to the company for more information:
Nader Pourhassan, PhD, CEO, npourhassan@cytodyn.com
Scott Kelly, MD, CMO, skelly@cytodyn.com
Thank you for taking the time to read this bulletin. I am
Sincerely,
CTMedic – Investors Hangout
https://investorshangout.com/CytoDyn-Inc-CYDY-60551/
Some of us want to disseminate relevant information on LL. I copied CTMedic's summary and edited it. Can some of you look it over and make sure it reads correctly?
I want to send it to persons who may have influence (whatever that means)
The web links do not work but will by the time I start sending it.
There is one kicker. I have no science background. Just editing. I have to sign it and put down CTMedic from this board. Should I just sign my name and this board? Unsure. It has to be legit.
To Whom it May Concern
CytoDyn, a small biotech company in Vancouver, WA has developed Leronlimab, a potent therapeutic for COVID-19 among other diseases. I own stock in CytoDyn and I am one of many shareholders who has volunteered to disseminate information of Leronlimab’s success when treating patients suffering from COVID-19.
There are hundreds of vaccines and therapeutics in development for COVID-19 and to date none with significant clinical effect. However, Leronlimab is a monoclonal antibody (mAb) with demonstrated efficacy in treating COVID-19 and the associated cytokine storm of immune dysregulation. A clinical trial of Leronlimab has been completed for the (M/M) mild/moderate patient population. This (M/M) trial demonstrated clinical and statistical significance and a request has been submitted to the FDA for (EUA) Emergency Use Authorization.
Leronlimab blocks the binding site of the CCR5 receptor on macrophages, T lymphocytes, and eosinophils. This stops chemotaxic trafficking of immune cells to areas of inflammation, halting the inflammatory cascade and the cytokine storm. Furthermore, blocking of CCR5 repolarizes macrophages and reverses exhaustion of CD8 lymphocytes, permitting normal immune function and resumption of antiviral activity through natural killer T-cells and granzyme-A antiviral production. In other words, by day 3, the COVID sufferer is already on the mend and within seven days is usually released from the hospital.
Former Stanford University Virologist, Dr. Bruce Patterson, described this mechanism of Leronlimab in a preprint on May 5: “Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277012/
CytoDyn has submitted top line data from a double blinded, placebo-controlled study to the FDA. Leronlimab demonstrates statistically significant improvement in NEWS2 (National Early Warning Score), a widely accepted UK clinical metric for measuring the progression of COVID-19 into the severe/critical phase. (P=0.02). Leronlimab showed clinical improvement in the NEWS2 score by 150%.
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19: https://clinicaltrials.gov/ct2/show/NCT043436...amp;rank=3
In addition, Leronlimab has demonstrated reduced mortality in the severe/critical population in over 70 EIND (Emergency Investigational New Drug) patients. A phase 3 trial is ongoing for this population, with an interim analysis of the data due in the coming weeks.
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19):
https://clinicaltrials.gov/ct2/show/NCT043472...amp;rank=4
CytoDyn does not yet have an FDA approval in any indication, so with cessation of EIND (Emergency Investigational New Drug) Leronlimab is unavailable to patients outside of clinical trial sites.
Please research CytoDyn, and reach out to the company for more information:
Nader Pourhassan, PhD, CEO, npourhassan@cytodyn.com
Scott Kelly, MD, CMO, skelly@cytodyn.com
Thank you for taking the time to read this bulletin. I am
Sincerely,
CTMedic – Investors Hangout
https://investorshangout.com/CytoDyn-Inc-CYDY-60551/
3
